ArticleBiomolecules & biomedicine2025
Risk factors and a nomogram for predicting valproic acid-induced liver injury : A nested case-control study.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk factors for liver injury induced by valproic acid (VPA) are not well understood, and no predictive tool currently exists to identify patients at risk. This study aims to explore these risk factors and develop a predictive model. We collected medical data from patients treated with VPA between January 1, 2020, and October 31, 2023. Prescription sequence analysis was used to identify patients with suspected VPA-induced liver injury, and the Roussel Uclaf Causality Assessment Method was applied to confirm the diagnosis. Risk factors were analyzed using logistic regression, and a nomogram model was developed and evaluated. A total of 256 cases were included in the study: 64 in the VPA-induced liver injury group and 192 in the control group. The incidence of liver injury was 5.3%. Multivariate logistic regression analysis revealed that dysglycemia (odds ratio [OR] = 5.171; 95% confidence interval [CI]: 1.254-21.325), hyperlipidemia (OR = 4.903; 95% CI: 1.400-17.173), surgery (OR = 10.020; 95% CI: 1.737-57.805), and hypokalemia (OR = 10.407; 95% CI: 2.398-45.173) were significant independent risk factors for VPA-induced liver injury. The area under the receiver operating characteristic curve was 0.904 (95% CI: 0.860-0.947), indicating excellent model performance. The Hosmer-Lemeshow test yielded a P value of 0.2671, and the calibration plot slope was close to one, further supporting the model's accuracy. The findings suggest that patients with dysglycemia, hyperlipidemia, a history of surgery, and hypokalemia are at higher risk for VPA-induced liver injury. The nomogram model provides a reliable method for predicting the likelihood of liver injury in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.